華伍股份(300095.SZ):目前尚未涉及聚變裝置特種制動系統的研發業務
格隆匯6月13日丨華伍股份(300095.SZ)於投資者互動平台表示,公司目前尚未涉及聚變裝置特種制動系統的研發業務。作為以工業制動系統為核心的高端裝備製造企業,公司始終專注於技術研發與產品升級,業務覆蓋港口起重機械、礦山冶金、風電新能源、軌道交通、工程機械等多個領域。未來,公司將在鞏固現有市場優勢的基礎上,積極把握新興行業機遇,拓展高附加值應用場景,以創新驅動發展,不斷提升核心競爭力與盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.